Clinical Trial Update: Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the optimal duration of anticoagulation therapy in low-risk pulmonary embolism patients with cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Pulmonary Embolism

Snippet

Sponsor: Takeshi Morimoto | Conditions: Venous Thrombosis, Neoplasms | Phase 4 | Status: COMPLETED